Cabaletta Bio Announces 2026 Strategic Priorities
Cabaletta Bio, Inc. (CABA)
Company Research
Source: GlobeNewswire
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics New durability data without preconditioning and higher dose initial clinical data from RESET-PV™ expected in 1H26; dose-ranging data from RESET-SLE™ without preconditioning anticipated in 2026 Complete Phase 1/2 data anticipated in lupus, scleroderma and myasthenia gravis in 1H26 FDA alignment on registrational study achieved in SLE and LN for small single-arm cohorts; strategically prioritizing no preconditioning regimen pending dose-ranging data PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical b
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- Cabaletta Bio Announces 2026 Strategic Priorities [Yahoo! Finance]Yahoo! Finance
- IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated PlatformsBusiness Wire
- Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio GAAP EPS of -$0.44 beats by $0.04 [Seeking Alpha]Seeking Alpha
CABA
Earnings
- 11/10/25 - Beat
CABA
Analyst Actions
- 10/31/25 - Cantor Fitzgerald
CABA
Sec Filings
- 1/12/26 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CABA's page on the SEC website